You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The PARP inhibitor was found to be most cost-effective as a maintenance treatment for those with a BRCA1 mutation and who receive chemo for more than six months.
The agency recommended the drug based on the results from the Phase III ALTA-1L trial, and after Takeda agreed to offer the drug to NHS England at a discount.
Once finalized, lung cancer patients in England can receive the drug for two years after they've received chemotherapy and if their tumors express PD-L1.
Using MammaPrint to guide breast cancer chemo de-escalation could result in significant healthcare savings in five of six evaluated countries, according to the analysis.
The Institute for Clinical and Economic Review is seeking public comment on its plan to evaluate the cost-effectiveness of EGFR inhibitors and immunotherapies.